HR+
Medical abbreviation · Hematology and Oncology
| Stands for | Hormone receptor-positive |
|---|---|
| Categories | Medical |
HR+ stands for Hormone receptor-positive, a hematology and oncology abbreviation.
Breast cancer whose cells express estrogen receptors, progesterone receptors or both, the most common breast cancer subtype. These tumors are treated with endocrine therapy that lowers estrogen or blocks its effects.
Example: HR+/HER2- metastatic breast cancer; first-line ribociclib plus letrozole.
Usage notes
Adjuvant endocrine therapy usually continues for 5 to 10 years because HR+ cancers can recur late, sometimes decades after diagnosis. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), first approved in 2015, prolong control of advanced disease, and some are used in high-risk early disease. Genomic tests such as Oncotype DX help decide which patients with early HR+ disease benefit from chemotherapy.
Related abbreviations
More hematology and oncology abbreviations
- HER2 – Human epidermal growth factor receptor 2
- HIT – Heparin-induced thrombocytopenia
- HL – Hodgkin lymphoma
- HLA – Human leukocyte antigen
- HLH – Hemophagocytic lymphohistiocytosis
- HNSCC – Head and neck squamous cell carcinoma
- HS – Hereditary spherocytosis
- HSCT – Hematopoietic stem cell transplantation
- Hyper-CVAD – Hyperfractionated cyclophosphamide, vincristine, Adriamycin…
- ICANS – Immune effector cell-associated neurotoxicity syndrome
- ICI – Immune checkpoint inhibitor
- IDA – Iron deficiency anemia
See all 144 hematology and oncology abbreviations →
This entry is for general education and is not medical advice. Abbreviation use varies between institutions; always confirm in context.